文献速递类风湿关节炎

患者特征影响类风湿关节炎生物制剂选择,并将使非TNFi生物制剂显得比TNFi生物制剂更有害

Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
PubMed 文献 · Ann Rheum Dis · 2017-12-13

瑞典登记研究纳入2011-2015年首次使用bDMARD的RA患者6481例及从TNFi转换的2829例,显示非TNFi组患者年龄更大、社会经济地位更低、疾病活动度更高且合并症负担更重;这些因素与治疗结局独立相关,导致非TNFi生物制剂(尤其利妥昔单抗)表观安全性和有效性更差,按TNFi组年龄/性别分布标准化后差异明显减小。

要点

  • 非TNFi组较TNFi组年龄更大、社会经济地位更低、疾病活动度及合并症负担更高,首次bDMARD时差异最明显。
  • 上述患者特征与治疗结局独立相关,使非TNFi生物制剂表观安全性和有效性更差,利妥昔单抗最极端。
  • 按TNFi组年龄/性别分布标准化后差异明显减小,提示非随机比较需校正患者特征。

核心结论

  • 瑞典RA患者中存在明显的渠道化现象,即年龄更大、健康状况更差的患者被分配至非TNFi生物制剂,尤其是作为首次bDMARD时。
  • 这种渠道化是否代表最大化的获益/风险比尚不清楚。
  • 除非校正年龄、病史和疾病活动度差异,否则这些差异将严重混杂非随机比较研究中对可用bDMARD安全性和有效性的评估。

研究设计与样本

  • 基于瑞典登记的研究,纳入2011-2015年首次使用bDMARD的RA患者(n=6481)及从TNFi转换后的患者(n=2829)。
  • 使用多变量回归模型评估人口学、临床特征和病史的组间差异。
  • 基于2006-2010年开始bDMARD的RA患者观察结局,通过回归模型计算患者特征对应的安全性和治疗结局预测差异。

主要发现

  • 开始非TNFi的患者较开始TNFi的患者年龄更大、社会经济地位更低、疾病活动度更高,且恶性肿瘤、严重感染和糖尿病等疾病负担更高。
  • 上述差异在首次bDMARD启动时最为明显。
  • 这些因素与治疗结局独立相关,导致非TNFi生物制剂表观安全性和有效性更差,利妥昔单抗最为极端。
  • 按TNFi组年龄/性别分布标准化后,差异明显减小。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: With the wide range of biological disease-modifying anti-rheumatic drugs (bDMARDs) available for treating rheumatoid arthritis (RA), and limited evidence to guide the choice for individual patients, we wished to evaluate whether patient characteristics influence the choice of bDMARD in clinical practice, and to quantify the extent to which this would bias direct comparisons of treatment outcome. METHODS: Register-based study of all Swedish patients with RA initiating necrosis factor inhibitor (TNFi), rituximab, abatacept or tocilizumab in 2011-2015 as their first bDMARD (n=6481), or after switch from TNFi as first bDMARD (n=2829). Group differences in demographics, clinical characteristics and medical history were assessed in multivariable regression models. Predicted differences in safety and treatment outcomes were calculated as a function of patient characteristics, through regression modelling based on observed outcomes among patients with RA starting bDMARDs 2006-2010. RESULTS: Patients starting non-TNFi were older than those starting TNFi, had lower socioeconomic status, higher disease activity and higher burden of diseases including malignancy, serious infections and diabetes. Differences were most pronounced at first bDMARD initiation. These factors were linked to treatment outcome independent of therapy, yielding worse apparent safety and effectiveness for non-TNFi biologics, most extreme for rituximab. Standardising to the age/sex distribution of the TNFi group reduced differences considerably. CONCLUSIONS: There was significant channelling of older and less healthy patients with RA to non-TNFi bDMARDs, in particular as first bDMARD. Whether this channelling represents a maximised benefit/risk ratio is unclear. Unless differences in age, medical history and disease activity are accounted for, they will substantially confound non-randomised comparative studies of available bDMARDs' safety and effectiveness.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Frisell T, Baecklund E, Bengtsson K, et al. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. Ann Rheum Dis. 2017. PMID: 29237621. doi:10.1136/annrheumdis-2017-212395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。